ArticleBMC gastroenterology2025
Clinical characteristics and factors associated with liver stiffness in patients with autoimmune liver disease: a cross-sectional study from the Kashgar region.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAutoimmune liver diseases (AILD) are a heterogeneous group of chronic inflammatory conditions characterized by progressive hepatic fibrosis. While liver stiffness measurement (LSM) has emerged as a valuable non-invasive assessment tool, its clinical utility and associated factors in AILD populations remain incompletely characterized, particularly in understudied ethnic populations.
methodsThis cross-sectional study enrolled 200 participants from January 2023 to January 2024, comprising 79 patients with AILD and 121 healthy controls from two tertiary hospitals in Kashgar region. All participants underwent comprehensive clinical assessment, biochemical evaluation, and LSM using transient elastography. Fibrosis staging in the AILD cohort was performed using a composite clinical algorithm incorporating clinical manifestations of portal hypertension, ultrasonographic features, biochemical indices, and available histopathology (n = 23, 29.1%). Correlation and multivariate regression analyses were used to identify factors independently associated with LSM values.
resultsPatients with AILD demonstrated significantly elevated LSM compared to controls (13.7 vs. 5.6 kPa, P < 0.001) with marked female predominance (83.5% vs. 47.9%, P < 0.001). LSM demonstrated a strong correlation with the clinically defined fibrosis stage, with values progressively increasing from stage S1 (10.2 kPa) to S4 (19.8 kPa). Multivariable analysis identified fibrosis stage (P = 0.003) and direct bilirubin (P = 0.045) as independent predictors of LSM values, whereas albumin demonstrated a strong inverse correlation (ρ=-0.67, P < 0.001). No significant differences in LSM were observed across the AILD subtypes after adjusting for the fibrosis stage (P = 0.36).
conclusionsLSM is strongly associated with clinically defined disease severity in patients with AILD. Integration with clinical parameters, including hepatic synthetic function and cholestatic markers, may enhance its clinical utility. However, validation against histological staging and in diverse populations is required before definitive conclusions regarding diagnostic accuracy can be made.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.